MORINAGA-MILK-INDUSTRY
30.5.2024 20:01:28 CEST | Business Wire | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, has announced a groundbreaking discovery in the fundamental research of Human-Residential Bifidobacteria (HRB). Through a joint collaboration with Kyoto University, the research has discovered that a specific type of bifidobacteria living in humans, also known as HRB, has the ability to convert precursors of a potentially harmful component into a beneficial metabolite. The research team has uncovered a previously unknown metabolic pathway utilized by the HRB species, converting indole, a potentially harmful compound, into the immunomodulatory metabolite indole-3-lactic acid (ILA). The findings, published in the prestigious journal "Gut Microbes" on May 5, 2024, underscore the unique capabilities of HRB as superior probiotics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530532346/en/
Human-Residential Bifidobacteria (HRB) strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63, significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1). Subsequently, the research demonstrated that HRB strains can convert the potentially harmful indole into tryptophan (Trp) and beneficial indole-3-lactate (ILA) (Figure 2). The study also identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3), highlighting the sophisticated mechanisms by which specific HRB strains contribute to gut health. (Graphic: Business Wire)
Research Background
The research focused on indole, a compound produced by certain intestinal bacteria, which is metabolized in the liver and converted into indoxyl sulfate, a typical urinary toxin. When renal function is impaired, indole and indoxyl sulfate can accumulate in the blood, leading to potential health issues, such as the progression of kidney dysfunction. The formation of indole, which is derived from tryptophan, an essential amino acid for humans, may lead to harmful impacts that are inevitable and pose significant health concerns. In collaboration with Kyoto University, Morinaga Milk’s new research aimed to investigate whether HRB strains could reduce the concentration of indole and transform it into a beneficial metabolite, and understand the underlying mechanism.
Groundbreaking Findings Backed HRB Superiority
- Reduction of Indole Concentration: The study revealed that a specific type of bifidobacteria living in humans, including Morinaga Milk’s HRB strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63 significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1).
- Conversion of Indole into Tryptophan (Trp) and Indole-3-Lactate (ILA): The research demonstrated that selected bifidobacterial strains, including Morinaga Milk’s HRB strains, can convert indole into tryptophan (Trp) and indole-3-lactate (ILA) (Figure 2). While tryptophan is a necessary amino acid, ILA has been identified as an immunomodulatory compound that supports intestinal and systemic immune health. This discovery marks a significant step forward in understanding how beneficial gut bacteria can transform harmful substances into compounds that promote health.
- Metabolic Pathway Elucidation: The study identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3). The researchers confirmed that selected bifidobacterial strains, including Morinaga Milk’s HRB strains can efficiently transform exogenous indole into ILA and Trp. This elucidation of the metabolic pathway provides a detailed understanding of the biochemical processes involved, highlighting the sophisticated mechanisms by which bifidobacteria contribute to gut health.
- Exclusive Presence in HRB: An extensive genome database search of 11,943 bacterial strains revealed that the co-occurrence of trpB and aldh genes is exclusive to HRB species. This specificity underlines the unique probiotic potential of these bifidobacteria in human health applications. The genomic analysis underscores the distinctiveness of HRB, positioning them as uniquely capable of performing these beneficial transformations.
Implications for Health
These findings highlight the potential of HRB strains, such as those commercialized by Morinaga Milk, in mitigating the harmful effects of indole by converting it into beneficial ILA. This novel function of bifidobacteria highlights their beneficial effects on human, where indole and its metabolites pose potential adverse health effects for individuals with high risks of chronic kidney disease. Moreover, the conversion of indole into tryptophan and ILA also suggests broader implications for overall gut health. Tryptophan is essential for protein synthesis and serves as a precursor for serotonin, a neurotransmitter that plays a critical role in mood regulation and overall well-being. The production of ILA, with its immunomodulatory properties, further supports the immune system, suggesting the additional health potentials of HRB as probiotics. These findings provide valuable insights into the reasons why HRB species thrive in the human intestinal tract and maintain a symbiotic relationship with the human host.
Continued Commitment to HRB Research
Morinaga Milk Industry remains dedicated to advancing our understanding of HRB and their health benefits. This discovery is a testament to our commitment to innovative research and developing high-quality, scientifically-backed probiotic products that contribute to human health and well-being. Our ongoing research endeavors aim to uncover even more ways in which HRB strains can benefit human health, reinforcing our position as a leader in the field of probiotics.
Embrace the Future: Aim Higher!
Under the Morinaga Milk Group's 10-Year Vision, the company aims to achieve an overseas sales ratio of 15% or more by the fiscal year ending March 2029. The company will continue its effort in developing and providing effective HRB probiotics with a higher level of safety and quality, aiming to strengthen its probiotic sales in the global marketplace to help achieve the goal.
About Morinaga Milk Industry
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530532346/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELLENiQ ENERGY and Chevron Sign Offshore Concession Agreements for Hydrocarbon Exploration and Production with the Hellenic Republic16.2.2026 19:07:00 CET | Press release
Marking a New Milestone in HELLENiQ ENERGY’s Upstream Portfolio HELLENiQ ENERGY, in collaboration with Chevron, signed today the Lease Agreements with the Hellenic Republic for the exploration of four offshore blocks located south of Crete and the Peloponnese, marking a significant milestone for Greece’s upstream development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216381183/en/ Snapshot from the signing of the lease agreements at the Maximos Mansion, attended by Prime Minister Kyriakos Mitsotakis. From left: Stavros Papastavrou, Minister of Environment and Energy; Andreas Shiamishis, CEO of HELLENiQ ENERGY; Gavin Lewis, VP Global New Ventures at Chevron; and Aristofanis Stefatos, CEO of HEREMA The successful consortium, with Chevron at 70% interest and being the Operator and HELLENiQ ENERGY at 30% interest, was selected following a competitive international tender launched by the Greek State in 2025. The four offs
Nexo Returns to the U.S.16.2.2026 17:00:00 CET | Press release
Nexo is relaunching its flagship Yield, Exchange, Loyalty, and Credit Lines in the United States. Nexo today announced its formal return to the United States market in 2026. The company’s official U.S. relaunch is being executed in partnership with regulated partners, providing a U.S.-compliant framework for the company’s investment and credit product offerings. Digital asset trading infrastructure is provided by Bakkt, a publicly listed U.S.-based digital asset platform purpose-built to support institutional risk management and compliance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216234514/en/ Nexo is relaunching its flagship Yield, Exchange, Loyalty, and Credit Lines in the United States. Nexo’s renewed presence in the United States follows a period of deliberate recalibration and reflects the company’s long-term commitment to operating in markets where regulatory frameworks are evolving, institutional standards a
TRU Simulation’s Full Flight Simulator for the Cessna Citation Ascend Achieves FAA Qualification, Expanding Advanced Training for Midsize Jet Pilots16.2.2026 16:00:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation, announced today its Full Flight Simulator (FFS) for the Cessna Citation Ascend has achieved Federal Aviation Administration (FAA) Level D qualification. This milestone significantly enhances advanced training options for midsize jet pilots, delivering a highly immersive and true-to-life training environment on the recently FAA certified Citation Ascend. European Union Aviation Safety Agency (EASA) qualification is anticipated in 2026, further extending the simulator’s global reach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216456292/en/ TRU Simulation’s Full Flight Simulator for the Cessna Citation Ascend achieves FAA qualification, expanding advanced training for midsize jet pilots “Pilots deserve training capabilities that reflect the advanced technology and performance that the Citation Ascend brings to the mid
AIT Worldwide Logistics Announces Strategic Partnership With Greenbriar Equity Group16.2.2026 15:03:00 CET | Press release
Agreement supports continuity, accelerating next phase of AIT’s growth plan Supply chain solutions leader AIT Worldwide Logistics (“AIT”) has entered into a definitive agreement to partner with Greenbriar Equity Group, L.P. (“Greenbriar”) in support of the global freight forwarder’s next chapter of growth. Financial terms of the private transaction were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216984391/en/ AIT Worldwide Logistics' strategic partnership with Greenbriar Equity Group represents one of the largest private acquisitions ever in the global freight forwarding sector. The deal marks the culmination of five successful years with The Jordan Company, L.P. (“TJC”). TJC, alongside key members of AIT’s executive leadership team, will remain invested in the company. Over the course of the company’s relationship with TJC, AIT has dramatically expanded its global footprint, acquired 14 businesses, and
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials16.2.2026 14:00:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The company will be disclosing new clinical data from Part A and Part B from COMP005 and Part A from COMP006. The results are scheduled for release on February 17th at 6:30 am ET, followed by a webinar hosted by Compass management at 8:00 am ET. Live Webcast Compass management will host a live audio webcast on February 17th at 8:00 am ET. The webcast will be accessible at this link: https://lifescievents.com/event/hz02j0rpw/ A replay of the webcast will be accessible for 30 days following the event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
